The HPV Vaccine: A Parent's Guide

What HPV is and why vaccination matters

Human papillomavirus (HPV) is a very common virus spread through skin-to-skin contact, including sexual contact. Most people are exposed at some point in their lives — studies suggest the majority of sexually active adults will have an HPV infection at some point. While most HPV infections clear on their own, certain high-risk strains can persist and cause cancers over many years — including cancers of the cervix, vulva, vagina, penis, anus, and throat .

The current 9-valent HPV vaccine targets the strains responsible for approximately 90% of HPV-related cancers. Cervical cancer — the most studied HPV-related malignancy — has seen dramatic reductions in precancerous lesions in countries with high vaccination rates. In Scotland, which achieved near-universal vaccination coverage, cervical cancer rates fell by nearly 90% in women who were vaccinated in childhood compared with unvaccinated cohorts, providing striking population-level evidence of the vaccine's impact. In the United States, about 36,000 HPV-related cancers occur each year in both men and women .

Why 11 to 12 is the recommended age

Two reasons drive the timing. First, the immune response to the HPV vaccine is significantly stronger at ages 11–12 than in older teens or adults, which is why two doses produce robust and lasting protection at this age but three doses are needed when vaccination begins at 15 or older 1Ref 1Centers for Disease Control and Prevention (2024).HPV Vaccine Recommendations.Two-dose schedule for series started before age 15; three-dose schedule for age 15+ or immunocompromised; routine vaccination at 11–12; catch-up through age 26; shared decision-making for ages 27–45; 6–12 month interval between doses. Second, the vaccine needs to be given before any potential HPV exposure — and that window closes at a different age for every individual, so vaccination in early adolescence is the safest public health approach.

Vaccination at 11 or 12 is not a statement about a child's current behavior or future choices. It is preventive care timed to biology and the strength of the immune response.

The two-dose vs. three-dose schedule

Two doses: When the series is started before the 15th birthday, current CDC guidelines require only two doses — ideally given 6 to 12 months apart 1Ref 1Centers for Disease Control and Prevention (2024).HPV Vaccine Recommendations.Two-dose schedule for series started before age 15; three-dose schedule for age 15+ or immunocompromised; routine vaccination at 11–12; catch-up through age 26; shared decision-making for ages 27–45; 6–12 month interval between doses. Starting earlier (at 11 or 12) means fewer injections for the same protection.

Three doses: When the series is started at age 15 or older — or in anyone who is immunocompromised — three doses are needed, given on a 0, 1–2, and 6-month schedule 1Ref 1Centers for Disease Control and Prevention (2024).HPV Vaccine Recommendations.Two-dose schedule for series started before age 15; three-dose schedule for age 15+ or immunocompromised; routine vaccination at 11–12; catch-up through age 26; shared decision-making for ages 27–45; 6–12 month interval between doses.

Catch-up vaccination is recommended through age 26 for those not adequately vaccinated earlier. Adults aged 27 to 45 may discuss vaccination with a provider through shared clinical decision-making 1Ref 1Centers for Disease Control and Prevention (2024).HPV Vaccine Recommendations.Two-dose schedule for series started before age 15; three-dose schedule for age 15+ or immunocompromised; routine vaccination at 11–12; catch-up through age 26; shared decision-making for ages 27–45; 6–12 month interval between doses.

The vaccine is recommended for boys too

HPV causes cancers in males as well as females — including cancers of the throat, penis, and anus . HPV-related oropharyngeal (throat) cancer, in particular, is rising and now affects more men than women in some countries. Vaccinating boys provides direct protection and also reduces transmission to future partners, regardless of those partners' gender. The CDC recommendation covers all children at ages 11–12 1Ref 1Centers for Disease Control and Prevention (2024).HPV Vaccine Recommendations.Two-dose schedule for series started before age 15; three-dose schedule for age 15+ or immunocompromised; routine vaccination at 11–12; catch-up through age 26; shared decision-making for ages 27–45; 6–12 month interval between doses.

Safety and what to expect at the visit

The HPV vaccine has been studied in large clinical trials and monitored in real-world surveillance systems across tens of millions of doses. More than 15 years of safety data confirm a favorable profile 2Ref 2Centers for Disease Control and Prevention (2024).Human Papillomavirus (HPV) Vaccine Safety.15+ years of safety monitoring; common reactions (injection site soreness, low-grade fever); no evidence linking HPV vaccine to infertility, autoimmune disease, or premature ovarian insufficiency. The most common reactions are soreness at the injection site (about 8 in 10 recipients notice it), headache, and occasionally a brief mild fever 2Ref 2Centers for Disease Control and Prevention (2024).Human Papillomavirus (HPV) Vaccine Safety.15+ years of safety monitoring; common reactions (injection site soreness, low-grade fever); no evidence linking HPV vaccine to infertility, autoimmune disease, or premature ovarian insufficiency. Fainting (vasovagal syncope) can occur after any injection in adolescents — particularly those who are anxious about shots — and providers typically ask teens to sit or lie down for 15 minutes after the vaccine.

There is no evidence linking the HPV vaccine to infertility, autoimmune disease, or premature ovarian insufficiency despite extensive research designed specifically to look for these signals 2Ref 2Centers for Disease Control and Prevention (2024).Human Papillomavirus (HPV) Vaccine Safety.15+ years of safety monitoring; common reactions (injection site soreness, low-grade fever); no evidence linking HPV vaccine to infertility, autoimmune disease, or premature ovarian insufficiency. The Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink have both been used to monitor the HPV vaccine since licensure; no unexpected serious safety signals have emerged at the population level. The HPV vaccine can be given at the same visit as other recommended adolescent vaccines — including Tdap and the meningococcal vaccine — without reducing effectiveness of any of them.